Menu Search
Equities

Tempus AI Inc

TEM:NSQ

Tempus AI Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)68.04
  • Today's Change-9.58 / -12.34%
  • Shares traded1.73m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Tempus AI Inc grew revenues 65.85% from 320.67m to 531.82m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -289.81m to -214.12m.
Gross margin53.18%
Net profit margin-116.06%
Operating margin-108.16%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Tempus AI Inc fell by 137.12m. Cash Flow from Financing totalled 117.55m or 22.10% of revenues. In addition the company used 214.34m for operations while cash used for investing totalled 40.31m.
Cash flow per share-5.26
Price/Cash flow per share--
Book value per share0.3459
Tangible book value per share-0.2184
More ▼

Balance sheet in USDView more

Tempus AI Inc has a Debt to Total Capital ratio of 89.10%.
Current ratio2.69
Quick ratio2.55
Total debt/total equity8.17
Total debt/total capital0.891
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.